Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Buffalo, New YorkAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Commack, New YorkAges 18 years+ - NCT06758401RecruitingPhase 3
Sigvotatug vedotin plus pembrolizumab for advanced lung cancer with high PD-L1
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
Nyack, New YorkAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if prostate biopsy is needed
This study tests whether a new blood test called Proclarix can better predict which men actually have prostate cancer before they undergo a biopsy. If the test works well, it could help avoid unnecessary biopsies in the future.
Middletown, New YorkAges 40–75 - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New York, New YorkAges 18 years+ - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Westbury, New YorkAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
The Bronx, New YorkAges 18 years+ - NCT03706027Recruiting
Compare two radiation timing plans for early lung cancer
This trial tests whether two different schedules (timing) of radiation have different side effects in people with early-stage non-small cell lung cancer. It may help reduce or better understand treatment toxicity while still treating the cancer.
Rochester, New YorkAges 18 years+ - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18–99 - NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99 - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Brooklyn, New YorkAges 18 years+ - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Commack, New YorkAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
New York, New YorkAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
New York, New YorkAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Rochester, New YorkAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT03193541Recruiting
Testing a urine blood test to check for bladder cancer risk
This trial checks whether a new lab test on urine can help sort out which people with small amounts of blood in the urine (microscopic hematuria) might have bladder cancer. It may help doctors evaluate symptoms more accurately and decide who needs further testing.
Rochester, New YorkAges 18–90 - NCT03213002RecruitingPhase 1/Phase 2
CAPTEM pills after brain radiation for newly diagnosed glioblastoma
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
New York, New YorkAges 18–74 - NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT03474913Recruiting
Upright MRI to help screen for prostate cancer
This study checks whether an MRI done while you are in an upright position can help with prostate cancer screening. If you have been advised to get a prostate MRI, the researchers may also do an ultrasound-guided biopsy to confirm results.
New York, New YorkAges 18–100 - NCT03492424Recruiting
Focal prostate cancer treatment study
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
New York, New YorkAges 18 years+ - NCT03694756Recruiting
Testing special MRI to see tiny breast cancer structures
This study is testing whether a special MRI scan can help show tiny features inside breast tumors (TMEM). It’s mainly a “feasibility” study, meaning the team is checking if the scan can be done safely and clearly in different types of operable breast cancer.
The Bronx, New YorkAges 18 years+ - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
New York, New YorkAges 18–90 - NCT03897270Recruiting
Breast cancer or healthy women for new breast imaging
This study tests a new way to look at the breast using photoacoustic imaging, alongside a breast MRI. It may help researchers see breast masses more clearly, even though it’s mainly for measuring how well the imaging works.
Buffalo, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- NYU Langone Health · 4 studies
- Weill Cornell Medicine · 4 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Roswell Park Cancer Institute · 3 studies
- State University of New York Upstate Medical University · 3 studies
- Brooklyn Methodist Hospital - NewYork Presbyterian · 2 studies
- Clinical Research Alliance · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.